Edgewise Therapeutics (EWTX) reported a Q4 net loss Monday of $0.42 per diluted share.
Analysts polled by FactSet expected a loss of $0.37.
As expected, the company did not report any revenue for the quarter ended Dec. 31. Meanwhile, operating expenses were $45.5 million for the quarter.
The clinical-stage biopharmaceutical firm said it ended Q4 with $470.2 million in cash, cash equivalents and marketable securities, which it expects to fund its current operating plan for "at least the next 12 months."
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.